Abstract:Vascular endothelial cells produce various biologically active factors regulating blood pressure, coagulation, and possibly cell growth of the vascular wall. Of the factors, nitric oxide (NO) has been the object of attention because of its quite simple molecular structure and variety of biological functions. In the present review, we focused on the physiologic and pathologic aspects of NO in hypertension. In experimental animals, both acute and chronic inhibition of NO synthase (NOS) with arginine derivatives produce a significant rise in blood pressure, indicating that tonic production of NO regulates basal vascular tonus. The chronic hypertension caused by NOS inhibitor is associated with cardiac hypertrophy and renal insufficiency. Sodium retention, though transient, and the plasma and tissue renin/angiotensin system in addition to the reduced production of NO have been implicated in the development of hypertension. Hypertension and the associated target organ failure can be reversed by co-administration of L-arginine or blockades of the renin/angiotensin system. Studies in which L-arginine as the substrate of NO or NOS inhibitor was administered demonstrated an important role of NO in the regulation of tonic vascular tonus also in normal subjects. In hypertensive subjects, however, endothelium-dependent vasorelaxation and production of NO are impaired, possibly due to a deficiency of L-arginine and/or a disorder of its utilization. Recent advances in the methods of detecting NO enabled us to demonstrate its diminished production from endothelial cells of hypertensive rats in vitro, although no definite biochemical evidence has been obtained in hypertensive subjects. The endothelial dysfunction, however, is not a primary cause of hypertension but a secondary result since it is commonly observed in various types of hypertension and can be reversed by correcting the blood pressure. Other common diseases including atherosclerosis and diabetes mellitus are also associated with similar abnormalities of the endothelium. NO has anti-atherogenic actions: inhibition of platelet functions and proliferation of vascular smooth muscle cells. Therefore, potentiation of endogenous NO and/or supplement of exogenous NO donors could be novel therapeutic approaches for the treatment of hypertension and atherosclerosis, while potential adverse effects of NO including cytotoxicity, immunosuppressibility, and hypotensive shock should be taken into account.

Effect of reduction of nitric oxide on plasma and kidney tissue angiotensin II levels

Increased Oxidative Stress in Rats with Chronic Nitric Oxide Depletion: Measurement of Urinary 8-Hydroxy-2'-deoxyguanosine Excretion.

Effect of angiotensin II on the renal response to amino acid in rats

N-004 INORGANIC NITRITE ATTENUATES ANGIOTENSIN II INDUCED CONTRACTION OF THE RENAL MICROCIRCULATION VIA XANTHINE OXIDASE-DEPENDENT NO PRODUCTION

Adenosine A(1)-Receptor Deficiency Diminishes Afferent Arteriolar And Blood Pressure Responses During Nitric Oxide Inhibition And Angiotensin Ii Treatment

Nitrite reduces angiotensin II-mediated contractions of the renal microcirculation by reducing NADPH oxidase activity and increasing nitric oxide bioavailability

Increased nitric oxide synthase activity despite lack of response to endothelium-dependent vasodilators in postischemic acute renal failure in rats.

Inhibition of endogenous nitric oxide synthase potentiates nitrovasodilators in experimental pulmonary hypertension

Relationship of angiotensinase and vasopressinase activities between hypothalamus, heart, and plasma in L-NAME-treated WKY and SHR

Renal Injury in Angiotensin II+L-NAME-induced Hypertensive Rats is Independent of Elevated Blood Pressure.

Angiotensin Receptor Neprilysin Inhibition mediates Renal Protection by ARNI (Sacubatril Valsartan) in Rats with Spontaneous Hypertension

Nitric Oxide-Compromised Hypertension: Facts and Enigmas

Interaction between Angiotensinase Activities in Pituitary and Adrenal Glands of Wistar-Kyoto and Spontaneously Hypertensive Rats under Hypotensive or Hypertensive Treatments

[Clinical significance of nitric oxide in hypertension]

Reduction of asymmetric dimethylarginine involved in the cardioprotective effect of losartan in spontaneously hypertensive rats.

EFFECT OF ANGIOTENSIN II RECEPTOR ANTAGONIST AND ENDOTHELIN RECEPTOR ANTAGONIST ON NITROGLYCERIN TOLERANCE IN RATS

Central Angiotensin Type 2 Receptor Stimulation Reduces Blood Pressure and Norepinephrine Excretion in Conscious Normal Rats

Renal protective effects of blocking the intrarenal renin-angiotensin system: angiotensin II type I receptor antagonist compared with angiotensin-converting enzyme inhibitor.

[Effects of Aldosterone on Inducible Nitric Oxide Synthase/nitric Oxide Pathway in Aortic Adventitia].

Role of Adenosine A1 Receptors in Regulation of Arteriolar Responses to Adenosine and Angiotensin Ii

The renoprotective effect of angiotensin-converting enzyme inhibitors in experimental chronic renal failure is not dependent on enhanced kinin activity